ESMO Asia 2025 - Gene Solutions Satellite Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025 - Gene Solutions Satellite Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025 - Gene Solutions Satellite Symposium
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Present at IASLC Asia Conference on Lung Cancer (ACLC) 2025: Empower Cancer Care with Advanced Multi-omics & AI
Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of
Gene Solutions’ HRD Insight Expands PARP Inhibitor Access for Ovarian Cancer Patients
First-of-its-kind study reveals high HRD prevalence in Vietnamese ovarian cancer patients and validates the performance of HRD Insight assay. Gene Solutions today announced the publication of a peer-reviewed study in
Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore
Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Present at IASLC Asia Conference on Lung Cancer (ACLC) 2025: Empower Cancer Care with Advanced Multi-omics & AI
Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of
Gene Solutions’ HRD Insight Expands PARP Inhibitor Access for Ovarian Cancer Patients
First-of-its-kind study reveals high HRD prevalence in Vietnamese ovarian cancer patients and validates the performance of HRD Insight assay. Gene Solutions today announced the publication of a peer-reviewed study in
Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore
Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
Gene Solutions to Present at IASLC Asia Conference on Lung Cancer (ACLC) 2025: Empower Cancer Care with Advanced Multi-omics & AI
Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of
Gene Solutions’ HRD Insight Expands PARP Inhibitor Access for Ovarian Cancer Patients
First-of-its-kind study reveals high HRD prevalence in Vietnamese ovarian cancer patients and validates the performance of HRD Insight assay. Gene Solutions today announced the publication of a peer-reviewed study in
Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore
Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Present at IASLC Asia Conference on Lung Cancer (ACLC) 2025: Empower Cancer Care with Advanced Multi-omics & AI
Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of
Gene Solutions’ HRD Insight Expands PARP Inhibitor Access for Ovarian Cancer Patients
First-of-its-kind study reveals high HRD prevalence in Vietnamese ovarian cancer patients and validates the performance of HRD Insight assay. Gene Solutions today announced the publication of a peer-reviewed study in
Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore
Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Present at IASLC Asia Conference on Lung Cancer (ACLC) 2025: Empower Cancer Care with Advanced Multi-omics & AI
Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of
Gene Solutions’ HRD Insight Expands PARP Inhibitor Access for Ovarian Cancer Patients
First-of-its-kind study reveals high HRD prevalence in Vietnamese ovarian cancer patients and validates the performance of HRD Insight assay. Gene Solutions today announced the publication of a peer-reviewed study in
Gene Solutions to Spotlight MRD and Multi-Omics at SSO ASM 2025 in Singapore
Singapore, September 2025 – Gene Solutions will host an exclusive symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” during the 10th Annual Scientific Meeting of the Singapore
Gene Solutions Announces SPOT MAS Multi-omic Dataset on 75 Cancer Subtypes
Singapore, 26 September 2025 SPOT-MAS is Gene Solutions’ AI-powered cfDNA platform for multi-cancer early detection (MCED) and tumor-of-origin (TOO) localization across 10 cancer groups—integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. Validated across multiple cancer types, the company today unveils
New BMC Biology study shows SPOT-MAS multi-omics cfDNA distinguishes early-stage breast cancer from benign lesions with high specificity.
The Gene Solutions research team, in collaboration with Ho Chi Minh City Oncology Hospital and several oncology centers, has published new peer-reviewed data in BMC Biology demonstrating that a multimodal
CAP-Accredited Laboratory
Gene Solutions uniquely operates 2 CAP-accredited laboratories specializing in next-generation sequencing (NGS), within a network of 7 NGS laboratories in Asia.
Gene Solutions joins an esteemed group of laboratories worldwide. This rigorous process ensures that we not only meet but exceed the highest standards of care, ultimately delivering the best possible outcomes for our patients.
Gene Solutions Genomics Singapore Laboratory CAP#9709518
